accountMarketWatch)- Biogen Idec Inc.'s /quotes/comstock/15*!biib/quotes/nls/biib BIIB +3.07% first-quarter profits rose 35% on growth of its multiple sclerosis drug portfolio, along with lower costs in the period. Overall the results from the Weston,...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Biogen Idec profit jumps 35% on MS drugs
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account